Medical Devices Industry Reports Implantable Drug Delivery Devices Market | Page 2

REPORT DESCRIPTION
Implantable Drug Delivery Devices Market – Overview
Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of blood clots. It is a serine
protease present in endothelial cells. With the help of serine protease, the conversion of plasminogen to plasmin is
catalyzed. Serine protease is a major enzyme for clot disintegration.
tPA is also be produced by using recombinant technology techniques known as recombinant tissue plasminogen
activator (rtPA). Specific rtPAs are tenecteplase, alteplase, and reteplase. These enzymes are used in clinical
treatment of thrombotic stroke or embolic stroke. tPA is a drug that dissolves blood clots. It is a thrombolytic
agent which can be administrated into the veins.
Tissue plasminogen activator is the first and only drug approved by the FDA in 1996 for the treatment of acute
ischemic stroke. Increasing incidences of stroke has boosted the tissue plasminogen activator market size.
According to John Hopkins Medicines (JHM) in the U.S., around 795,000 people in the U.S. suffer from stroke
per year, as reported in 2014. According to the World Health Organization (WHO), stroke is the second leading
cause of death and the third leading cause of disability, worldwide, as reported in 2012. This is one of the major
factors driving the tissue plasminogen activator market growth.